ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ELUTIA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.82+0.02 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
ELUTIA INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Women's Health | $1.28M | $2.09M | $2.12M | $2.38M | $2.01M | $2.63M | $2.32M | $3.10M | $2.57M | $3.57M | – | – | 52.9% | -36.2% |
| Cardiovascular | $1.14M | $1.03M | $1.15M | $944.00K | $736.00K | $326.00K | $501.00K | $562.00K | $1.08M | $770.00K | – | – | 47.1% | +55.4% |
| Device Protection | – | – | – | – | $3.52M | $3.08M | – | – | $2.64M | $2.36M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Women's Health | – | – | – | – | – | – | – | $3.10M | $2.57M | $3.57M | $3.00M | $2.61M | – | – |
| Cardiovascular | – | – | – | – | – | – | – | $562.00K | $1.08M | $770.00K | $626.00K | $938.00K | – | – |
| Device Protection | – | – | – | – | – | – | – | $2.26M | $2.64M | $2.36M | $2.25M | $2.58M | – | – |
By region
From the segment and revenue-disaggregation notes of Elutia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.